Posts in category Business Standard
Forbes & Company fixes record date for scheme of arrangement (23-02-2024)
Record date is 07 March 2024
Select mutual funds pull the plug on transaction charges to distributors (23-02-2024)
SBI, DSP, PGIM India among fund houses that have stopped paying the fee
Juniper Hotels IPO subscribed 2.07 times on concluding day of the issue (23-02-2024)
The company's Rs 1,800-crore IPO was entirely a fresh issue and was priced between Rs 342 to Rs 360 per share. At the top end of the price band, Juniper is valued at around Rs 8,000 crore
Konkan Railway Corporation standalone net profit declines 23.01% in the December 2023 quarter (23-02-2024)
Sales decline 19.66% to Rs 983.42 crore
Enkei Wheels India reports standalone net profit of Rs 2.11 crore in the December 2023 quarter (23-02-2024)
Sales rise 34.65% to Rs 200.25 crore
Juniper Hotels IPO subscribed 2.07 times (23-02-2024)
The offer received bids for 5.99 crore shares as against 2.89 crore shares on offer.
Benchmarks end flat, Nifty settles below 22,250; VIX slips below 15 (23-02-2024)
Domestic stock market closed flat on Friday after reaching record highs in early trade. Investor caution prevailed due to upcoming releases of key domestic economic data, leading to a reluctance in taking long positions. The data to be released on 29th February 2024 includes India's Q3 GDP data, fiscal deficit numbers for January, and eight infrastructure industries data. The Nifty50 concluded below the 22,250 mark after hitting a record high of 22,297.50 in early trade. Within sectors, media, realty, and consumer durables shares saw gains, whereas PSU banks and oil & gas stocks experienced declines.
GPT Healthcare IPO subscribed 85% (23-02-2024)
The offer received bids for 1.67 crore shares as against 197.63 crore shares on offer.
SG Mart allots 5.57 crore equity shares under bonus issue (23-02-2024)
Powered by Capital Market - Live News
Orchid Pharma receives USFDA approval for Enmetazobactam (23-02-2024)
Orchid Pharma has received approval by the United States Food and Drug Administration (USFDA) for its novel invention, Enmetazobactam'. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA).